Market news

AbbVie shares: Phase 1 data for weekly ABBV-295 amylin analog shows up to ~10% weight loss, supporting Phase 2 plans—read the key results now.

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.84% on an annualized basis producing an average annual return of 15.37%. Currently, AbbVie has a market capitalization of $465.70 billion.

AbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.

ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.

CNBC’s final trades: Weiss picked UnitedHealth, Lebenthal chose AbbVie after FDA approval, and Terranova backed Okta amid raised price targets.

AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

Alphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns.

ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the […]

FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.

AbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology. The partnership will use Iambic’s Enchant v3 model, which is trained on more than 6,000 molecular properties and is designed to evaluate multiple drug characteristics simultaneously. The companies will pursue candidates […]

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

AbbVie (ABBV) said Thursday that Health Canada issued a Notice of Compliance for EPKINLY, or epcorit

AbbVie is rated a "Sell" with a $191 target, implying 27.7% downside from the current $264 price. Click here to read more about the ABBV stock.

AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.

Johnson & Johnson vs. AbbVie valuation: JNJ’s P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis. The approval covers patients who did not respond to, or could not tolerate, standard disease-modifying drugs. It is the eleventh indication Rinvoq holds in Europe. The Commission also cleared […]

ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.

AbbVie (NYSE:ABBV) announced on Tuesday that the European Commission has approved Rinvoq (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis. The approval covers children aged two years and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

An official report on September 18, 2026 reveals Representative Pete Sessions's recent sale of AbbVie (NYSE:ABBV) stock, valued between $30,002 and $100,000. The transaction took place on September 14, 2026, as per

AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug

AbbVie's market-beating days don't seem to be over yet.

AbbVie (NYSE:ABBV) shared new real-world and pediatric safety data for VRAYLAR in MDD and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups. Pediatric data for VRAYLAR added information on safety and use in younger patients with mood disorders. The fresh VRAYLAR real-world and pediatric results sit against a wider backdrop our research has uncovered. Check out 4 warning signs that...

AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, 2026, to shareholders of record as of October 15. There is no new increase this time, since AbbVie has kept its quarterly dividend at $1.73 throughout 2026. Still, the latest declaration confirms the higher payout […]

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I). The findings reinforce that the efficacy established in clinical trials translates to effectiveness in the broader, more clinically complex patient populations healthcare providers treat every day.

Key Stats for AbbVie StockCurrent Price: $263. 04Target Price (Mid): ~$361Street Target: ~$279Potential Total Return: ~37% (over ~4.